Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

NCT00150449 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 511

Last updated 2006-07-14

No results posted yet for this study

Summary

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

Conditions

  • Anxiety Neuroses

Interventions

DRUG

Pregabalin

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Completion
2006-03-31

Countries

  • Austria
  • Belgium
  • Estonia
  • France
  • Germany
  • Israel
  • Italy
  • Latvia
  • Netherlands
  • Poland
  • South Africa
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00150449 on ClinicalTrials.gov